RareWays is a research directory. It helps you understand the science. It is not medical advice. Always discuss your care options with your healthcare team.
Coverage: 2020-01-01 onwards, with up to 300 results per query from PubMed and Europe PMC and separate limits on other sources. This is a selected index, not a complete literature search.
Updates are delayed or unverified. Check original sources for the latest information.
Your saved research and appointment questionsView recorded trial and retraction changes
Nephroblastoma: Research Summary
Printed from RareWays (rareways.org)
For general awareness only. Not medical advice. Discuss all care options with your healthcare team.
5 Most Recent Research Articles
- 1.
Direct correlation of intravoxel incoherent motion imaging based on implicit neural representations and histopathology in pediatric Wilms’ tumors: can it differentiate between subtypes?
Arends GC (18 October 2026)
https://doi.org/10.21203/rs.3.rs-11362141/v1
- 2.
Assessment of narrative operative reports for Wilms tumor resection using consensus-based component criteria at Tikur Anbessa Specialized Hospital
Alemayehu Girma et al., BMC Surgery (17 October 2026)
https://doi.org/10.1186/s12893-026-04272-6
- 3.
Bilateral Wilms Tumor: Multi-institutional Analysis of Nephron-Sparing Surgery at Centers with Focused Wilms Tumor Expertise.
Murphy Andrew J et al., Journal of pediatric surgery (16 October 2026)
https://pubmed.ncbi.nlm.nih.gov/42887651/
- 4.
Mapping the Knowledge Structure and Thematic Trends of Wilms Tumor: Insights From Text Mining
Boshen Shu et al., Organ medicine. (13 October 2026)
https://doi.org/10.1002/orm2.70055
- 5.
Direct correlation of intravoxel incoherent motion imaging based on implicit neural representations and histopathology in pediatric Wilms tumors: can it differentiate between subtypes?
G. C. Arends et al., arXiv (Cornell University) (13 October 2026)
https://doi.org/10.48550/arxiv.2610.18728
Clinical Trials : Currently Recruiting (Australia)
Ask your doctor whether you or your child may be eligible for any of these trials. Each has its ID and full eligibility criteria at the link shown.
- 1.
A Study Using Risk Factors to Determine Treatment for Children With Favorable Histology Wilms Tumors (FHWT)
NCT06401330 · Recruiting · Phase 3 · Children's Oncology Group
Up to age 30
https://clinicaltrials.gov/study/NCT06401330
- 2.
A Study of Combination Chemotherapy for Patients With Newly Diagnosed DAWT and Relapsed FHWT
NCT04322318 · Recruiting · Phase 2 · Children's Oncology Group
Up to age 30
https://clinicaltrials.gov/study/NCT04322318
Source: RareWays research directory. Data from PubMed, Europe PMC, OpenAlex, ClinicalTrials.gov.
Always verify information with your healthcare team before making any decisions about your care.
Nephroblastoma
Nephroblastoma, also called Wilms tumour, is a rare cancer of the kidney that mostly affects young children. It develops from immature kidney cells and often appears as a painless lump or swelling in the abdomen. Treatment usually combines surgery, chemotherapy and sometimes radiotherapy, and most children are cured with modern treatment.
This overview is general information, not an individual medical assessment. Research is selected automatically and may include mismatches. How we select and explain research.
Most Recent Research
<title>Abstract</title> <p> <bold>Background:</bold> Wilms tumor (WT) is a heterogeneous pediatric renal malignancy. Invasive procedures to establish histology prior to pre-operative treatment are not recommended by the International Society of Pediatric (SIOP) Oncology Renal Tumor Study Group, yet different tissue components are associated with different responses to therapy (SIOP Umbrella protocol). Intravoxel incoherent motion (IVIM) magnetic resonance imaging (MRI) may improve subtype differentiation before surgery as a noninvasive radiographic biomarker by capturing both diffusion and perfusion characteristics, as opposed to the conventionally-used apparent diffusion coefficient (ADC). The objective of this study is to evaluate the discriminative performance of IVIM MRI in differentiating WT subtypes. IVIM provides quantitative parameters that disentangle the diffusion coefficient (D), incoherent blood flow (pseudodiffusion, D*) and perfusion fraction (f). <bold>Materials and methods:</bold> This retrospective study included thirthy children with WT. Standardized 1.5T MRI with 10-b-value diffusion weighted imaging (DWI) was performed. IVIM parameters were estimatedusing a self-supervised implicit neural representations network and were correlated with histopathology via a patient-specific 3D-printed cutting guide. Statistical analyses included mixed models, receiver operating curve analysis, and logistic regression. <bold>Results:</bold> Thirty lesions were MRI–histopathology correlated on slice-level. Significant subtype differences were observed for D* stromal versus epithelial (p = 0.024), regressive tumors (p = 0.031) and mixed WT tumors (p = 0.043). ADC showed no significant subtype differences. <bold>Conclusions:</bold> Direct MRI–histopathology correlation enabled differentiation between stromal subtype andepithelial, mixed and regressive subtype on macroscopic slice level using D*. Future research should focus on data addition and optimizing equal representation of different tissue types. </p>
Common Questions
What is Nephroblastoma?
Nephroblastoma, also called Wilms tumour, is a rare cancer of the kidney that mostly affects young children. It develops from immature kidney cells and often appears as a painless lump or swelling in the abdomen. Treatment usually combines surgery, chemotherapy and sometimes radiotherapy, and most children are cured with modern treatment.
How many clinical trials are available for Nephroblastoma?
RareWays currently indexes 78 clinical trials for Nephroblastoma, of which 17 are actively recruiting. These counts cover indexed trials across countries, not just your country. An Australian site does not necessarily mean that site is recruiting. Check locations, eligibility and current availability with the study team.
Where does the research data for Nephroblastoma come from?
RareWays aggregates research from PubMed, Europe PMC, OpenAlex, and ClinicalTrials.gov. Data is refreshed automatically every day. All articles and trials link directly to their original sources.
Get research updates
Monthly email when new findings are published for Nephroblastoma.
Your email and selected disease are stored for these updates. Unsubscribe any time. Privacy and deletion.
This information is for general awareness only.
For guidance specific to your situation, please speak with your healthcare team.